Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a salt substitute help kidney patients? small study aims to find out

NCT ID NCT05558267

Knowledge-focused Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study will test whether a potassium-containing salt substitute is safe for people with end-stage kidney disease on hemodialysis. Twenty participants will use the salt substitute for 16 days and regular table salt for 16 days, with a break in between. Researchers will measure potassium levels and watch for side effects like dangerously high potassium.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
potassium-containing salt substitute (Morton Lite Salt)
What this could lead to
If successful, this could point toward a safer way for kidney dialysis patients to use salt without dangerously raising potassium levels.
What could go wrong
This is a very small pilot study with only 20 participants, so results may not apply to everyone. The salt substitute could cause dangerously high potassium (hyperkalemia) in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Receiving outpatient maintenance HD therapy. 2. Age ≥ 21 years. 3. Negative serum pregnancy test for women of child-bearing capacity. Childbearing capacity will be defined by report of menstruation within ≤ 6 months. Exclusion Criteria: 1. Currently incarcerated. 2. Insufficient capacity for informed consent. 3. Non-hemolyzed serum potassium concentration \>6.0 mEq/L within ≤30 days. 4. Unscheduled HD for hyperkalemia within ≤30 days. 5. Attendance at ≤10 of last 13 scheduled OP HD sessions. 6. Co-habiting family member with known hyperkalemia. 7. Co-habiting family with ≥stage 3b chronic kidney disease or chronic kidney disease of unknown severity. 8. Hemoglobin \< 8.0 mg/dL. 9. Use of other potassium supplements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage kidney disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End-stage kidney disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • NYU Langone Health

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.